Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular diseases, muscle wasting, liver and kidney diseases, and others. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone858-550-7500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$251.45 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Ligand Pharmaceuticals (NASDAQ:LGND) Frequently Asked Questions
What is Ligand Pharmaceuticals' stock symbol?
Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."
How were Ligand Pharmaceuticals' earnings last quarter?
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) issued its earnings results on Thursday, February, 7th. The biotechnology company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.22 by $0.48. The biotechnology company had revenue of $59.59 million for the quarter, compared to the consensus estimate of $52.58 million. Ligand Pharmaceuticals had a return on equity of 26.00% and a net margin of 57.00%. The company's revenue was up 18.1% compared to the same quarter last year. During the same period last year, the business posted $1.31 EPS. View Ligand Pharmaceuticals' Earnings History.
When is Ligand Pharmaceuticals' next earnings date?
What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?
Ligand Pharmaceuticals issued an update on its FY19 earnings guidance on Thursday, February, 7th. The company provided EPS guidance of ~$6.05 for the period, compared to the Thomson Reuters consensus estimate of $5.53. The company issued revenue guidance of ~$224 million, compared to the consensus revenue estimate of $213.42 million.Ligand Pharmaceuticals also updated its FY 2019 guidance to $6.05-6.05 EPS.
What price target have analysts set for LGND?
6 equities research analysts have issued 12 month price objectives for Ligand Pharmaceuticals' shares. Their forecasts range from $150.00 to $260.00. On average, they expect Ligand Pharmaceuticals' stock price to reach $224.6667 in the next twelve months. This suggests a possible upside of 79.9% from the stock's current price. View Analyst Price Targets for Ligand Pharmaceuticals.
What is the consensus analysts' recommendation for Ligand Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ligand Pharmaceuticals.
What are Wall Street analysts saying about Ligand Pharmaceuticals stock?
Here are some recent quotes from research analysts about Ligand Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Ligand reported encouraging fourth-quarter results, beating estimates on both counts. The company’s Captisol Formulation technology resulted in partnerships with several leading drug companies like Novartis and Amgen that provide it with funds in the form of milestone and royalty payments. Ligand is acquiring other technology platforms like OmniAb platform from OMT acquisition to reduce dependence on Captisol formulation. OmniAb is likely to drive future revenues. Shares of Ligand have underperformed the industry so far this year. Following the sale Promacta rights, the company will derive a substantial portion of its revenues from royalties associated with the sales of Kyprolis. The drug has shown encouraging growth ans achieved blockbuster status in 2018. However, any setback related to this product could have a substantial impact." (3/19/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $254 price target. Our target is based on sum of the parts including: (1) a clinical NPV model of assets in Phase 2 development or greater (currently 30 out of over 200 assets under development); and (2) NPV of current revenues based on our projections for royalties, material sales, and collaborative revenue." (3/13/2019)
Has Ligand Pharmaceuticals been receiving favorable news coverage?
Media stories about LGND stock have been trending somewhat negative this week, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Ligand Pharmaceuticals earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
Who are some of Ligand Pharmaceuticals' key competitors?
Some companies that are related to Ligand Pharmaceuticals include Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), SAGE Therapeutics (SAGE), Loxo Oncology (LOXO), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), Marina Biotech (MRNA), Catalent (CTLT), Nektar Therapeutics (NKTR), Amarin (AMRN), Alkermes (ALKS) and United Therapeutics (UTHR).
What other stocks do shareholders of Ligand Pharmaceuticals own?
Who are Ligand Pharmaceuticals' key executives?
Ligand Pharmaceuticals' management team includes the folowing people:
- Mr. John L. Higgins, CEO & Exec. Director (Age 49)
- Mr. Matthew W. Foehr, Pres & COO (Age 46)
- Mr. Matthew Korenberg, Exec. VP of Fin. & CFO (Age 44)
- Mr. Charles S. Berkman, Sr. VP, Gen. Counsel & Sec. (Age 50)
- Mr. Todd Pettingill, Director of Corp. Devel.
Who are Ligand Pharmaceuticals' major shareholders?
Ligand Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.99%), Millennium Management LLC (2.57%), Conestoga Capital Advisors LLC (2.29%), Victory Capital Management Inc. (2.21%), Eagle Asset Management Inc. (2.09%) and Macquarie Group Ltd. (2.07%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba and Todd C Davis. View Institutional Ownership Trends for Ligand Pharmaceuticals.
Which institutional investors are selling Ligand Pharmaceuticals stock?
LGND stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Mackay Shields LLC, FMR LLC, Principal Financial Group Inc., Bank of New York Mellon Corp, Prudential Financial Inc., Conestoga Capital Advisors LLC and Castleark Management LLC. Company insiders that have sold Ligand Pharmaceuticals company stock in the last year include Charles S Berkman, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr and Todd C Davis. View Insider Buying and Selling for Ligand Pharmaceuticals.
Which institutional investors are buying Ligand Pharmaceuticals stock?
LGND stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Thrivent Financial for Lutherans, Norges Bank, Jennison Associates LLC, Two Sigma Investments LP, Macquarie Group Ltd., RK Capital Management LLC and Canada Pension Plan Investment Board. Company insiders that have bought Ligand Pharmaceuticals stock in the last two years include Jason Aryeh and John L Higgins. View Insider Buying and Selling for Ligand Pharmaceuticals.
How do I buy shares of Ligand Pharmaceuticals?
Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ligand Pharmaceuticals' stock price today?
One share of LGND stock can currently be purchased for approximately $124.86.
How big of a company is Ligand Pharmaceuticals?
Ligand Pharmaceuticals has a market capitalization of $2.55 billion and generates $251.45 million in revenue each year. The biotechnology company earns $143.32 million in net income (profit) each year or $6.28 on an earnings per share basis.
What is Ligand Pharmaceuticals' official website?
How can I contact Ligand Pharmaceuticals?
Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]
MarketBeat Community Rating for Ligand Pharmaceuticals (NASDAQ LGND)
MarketBeat's community ratings are surveys of what our community members think about Ligand Pharmaceuticals and other stocks. Vote "Outperform" if you believe LGND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LGND will underperform the S&P 500 over the long term. You may vote once every thirty days.
